ABATACEPT IN TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS: INTERNATIONAL DATA AND EXPERIENCE OF USAGE IN THE REPUBLIC OF MORDOVIA

Abstract

The authors represent a review of modern views on abatacept usage in treatment of juvenile idiopathic arthritis emphasizing its high level of safety and possibility to use it in patients resistant to standard basic therapy and tumor necrosis factor alfa inhibitors. The results of clinical investigations on assessment of efficacy and safety of abatacept in treatment of various types of rheumatoid arthritis in adults and juvenile idiopathic arthritis in children are given. Among the advantages and prospects of abatacept usage in pediatric rheumatology is possibility to its administration as monotherapy, particularly in patients with intolerability or insufficient efficacy of methotrexate and/or tumor necrosis factor . The authors also show their own data on abatacept usage in 8 children with juvenile idiopathic arthritis in the Republic of Mordovia, among them — patients with high risk of tuberculosis infection activation. In 1 year 75% of children (half of them being resistant to genetically engineered biological agents) achieved 50% improvement according to the pediatric criteria of the American College of Rheumatology.

Keywords

• juvenile idiopathic arthritis
• rheumatoid arthritis
• abatacept